Showing results (1271-1280 of 5,986) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|April 20, 2023
Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR InhibitorsAudrey Turchick, Astrid Zimmermann, Li-Ya Chiu, et al.
Molecular Cancer Therapeutics|March 31, 2023
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET AlterationsJoachim Albers, Manja Friese-Hamim, Anderson Clark, et al.
Molecular Cancer Therapeutics|April 4, 2023
BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint BlockadeBrian M Olson, Kiranj Chaudagar, Riyue Bao, et al.
Molecular Cancer Therapeutics|March 31, 2021
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ InhibitionLarissa S Carnevalli, Molly A Taylor, Matthew King, et al.
Molecular Cancer Therapeutics|March 18, 2015
MGMT Expression Predicts PARP-Mediated Resistance to TemozolomideOihane Erice, Michael P Smith, Rachel White, et al.
Molecular Cancer Therapeutics|August 14, 2020
Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody-Drug Conjugate in Patient-derived XenograftsAdnan O Abu-Yousif, Donna Cvet, Melissa Gallery, et al.
Molecular Cancer Therapeutics|August 6, 2020
PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling AnalysisJames T Lim, Neha Singh, Libia A Leuvano, et al.
Molecular Cancer Therapeutics|April 3, 2021
F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCydJoel Morris, Donn G Wishka, Omar D Lopez, et al.
Molecular Cancer Therapeutics|April 13, 2021
Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in GlioblastomaMiguel Jiménez-Alcázar, Álvaro Curiel-García, Paula Nogales, et al.
Molecular Cancer Therapeutics|July 31, 2012
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancerTakayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, et al.
Pageof 599